SCHEMBL3589681

SCHEMBL3589681

Fc1ccc(Oc2cnc(Nc3cccc(OCc4ccccc4)c3)nc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.48
MAOB P27338 3/20 0.48
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
PTK6 Q13882 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
RECQL P46063 2/20 0.46
APP P05067 1/20 0.46
CDK2 P24941 1/20 0.46
CDK9 P50750 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 1/20 0.46
BLM P54132 1/20 0.46
CASP6 P55212 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653527 0.87 MAOB (0.47) MAOBCTSVCTSLPTK6SIRT2
SCHEMBL3594258 0.85 CTSV (0.56) SYKMAOBCTSVCTSLPTK6
SCHEMBL3581486 0.83 APP (0.63) SYKMAOBCTSVCTSLPTK6
SCHEMBL3596154 0.83 KCNH2 (0.51) SYKKMT2AMEN1CDK2LMNA
SCHEMBL3595604 0.82 CDK8 (0.49) SYKKMT2AMEN1ALDH1A1APP
SCHEMBL8067028 0.81 PRKAA2 (0.46) MAOBCTSVCTSLSIRT2KMT2A
SCHEMBL3583812 0.81 SYK (0.61) SYKKMT2AMEN1APPCDK2
SCHEMBL14379768 0.81 CTSV (0.53) SYKMAOBCTSVCTSLPTK6
SCHEMBL3586436 0.81 MAOB (0.57) SYKMAOBCTSVCTSLPTK6
SCHEMBL3600524 0.81 APP (0.62) SYKMAOBAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
EP-2010502-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2009-01-07 EP disclosed
WO-2007125351-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES TYMP, APP, HTT SYK 3311/4885MAOB 313/4885CTSV 2095/4885
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES TYMP, APP, HTT SYK 3311/4885MAOB 313/4885CTSV 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.